Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
WNT974 · 1 trial · 1 indication
Phase Ib: To estimate the MTD(s) and/or RP2D(s) of the triple combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant, KRAS wild-type (WT) mCRC harboring upstream Wnt pathway mutations.
Phase II: To estimate the preliminary anti-tumor activity of the RP2D(s) of the combination of WNT974, LGX818 and cetuximab in patients with BRAFV600-mutant metastatic CRC harboring upstream Wnt pathway mutations
| Arm | Type | Description |
|---|---|---|
| WNT974, LGX818 and cetuximab combo | EXPERIMENTAL | Phase l: Dose Escalation phase; Phase ll: SIngle group assessing the triple combination of WNT974, LGX818 and cetuximab |
| Name | Type | Description |
|---|---|---|
| WNT974 | DRUG | - |
| LGX818 | DRUG | - |
| Cetuximab | BIOLOGICAL | - |
Inclusion Criteria: * Male or female aged ≥ 18 years * Histological or cytological confirmed metastatic colorectal cancer * Written documentation of KRAS wild-type status and BRAFV600-mutation with RNF43 mutation and/or RSPO fusion * Progression of disease after at least one prior standard of care ...
Top 20 of 77 competitors
WNT974 is an investigational small molecule being studied for the treatment of metastatic colorectal cancer (mCRC). It was evaluated in a Phase 1 clinical trial in combination with LGX818 and cetuximab in patients with BRAF-mutant mCRC and Wnt pathway mutations. The drug is not approved and remains in clinical development.
WNT974 targets the Wnt signaling pathway, which is implicated in cancer growth. It is being studied in patients with BRAF-mutant metastatic colorectal cancer who also have Wnt pathway mutations. The drug is designed to inhibit Wnt signaling, potentially slowing tumor progression in this specific patient population.
WNT974 is being developed by Pfizer, Inc., a biopharmaceutical company listed on the New York Stock Exchange under the ticker symbol PFE. Pfizer is conducting clinical research on this investigational drug for the treatment of metastatic colorectal cancer.
WNT974 is in Phase 1 clinical development. It has completed a Phase 1 trial, and it is not FDA approved. The drug remains investigational, meaning it has not yet been authorized for commercial use and is still being evaluated for safety and efficacy in clinical studies.
WNT974 has been studied in one completed Phase 1 clinical trial, identified as NCT02278133. This trial evaluated WNT974 in combination with LGX818 and cetuximab in patients with BRAF-mutant metastatic colorectal cancer and Wnt pathway mutations. The study enrolled 20 participants across multiple countries.
No, WNT974 is a distinct investigational drug, not the same as LGX818 or cetuximab. In the clinical trial, WNT974 was tested in combination with LGX818 and cetuximab. LGX818 is a BRAF inhibitor and cetuximab is an EGFR inhibitor, while WNT974 targets the Wnt pathway.